ABBV vs PG: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Procter & Gamble Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-17.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
The Procter & Gamble Company · Consumer Defensive
$147.04
+14.4% upside to fair value
Med Conviction
Grade B+
High Quality
QuantHub Verdict
PG has more upside to fair value
(+14.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PG |
| Current Price |
$261.70 |
$147.04 |
| Fair Value Estimate |
$259.04 |
$168.19 |
| Upside to Fair Value |
-1.0%
|
+14.4%
|
| Market Cap |
$462.4B |
$349.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
17.6x
|
| Price / Sales |
7.2x
|
4.0x
|
| Price / FCF |
23.6x
|
22.4x
|
| Revenue Growth YoY |
+10.2%
|
+1.5%
|
| Gross Margin |
71.5%
|
50.2%
|
| Operating Margin |
29.3%
|
22.7%
|
| Return on Equity |
-136.5%
|
29.8%
|
| Dividend Yield |
2.61% |
2.92% |
| FCF Yield |
4.25%
|
4.47%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Procter & Gamble is a global consumer-staples leader selling daily-use products across beauty, grooming, health care, fabric and home care, and baby, feminine and family care in about 180 countries. Business quality is high because its brands, consumer insight, R&D, marketing scale and global distribution underpin leading category positions, including over 60% in blades and razors and over 35% in…
Accumulation Zones
| Metric |
ABBV |
PG |
| Zone Low |
$194.28 |
$126.14 |
| Zone High |
$220.18 |
$142.96 |
| In Buy Zone? |
No
|
No
|